Información*
| Nombre | DAVID JOSE HEREDIA VAZQUEZ |
|---|---|
| Área | MEDICINA Y CIENCIAS DE LA SALUD |
| Campo | ESPECIALIDAD MÉDICA |
| Disciplina | ONCOLOGÍA |
| Especialidad | MEDICINA INTERNA |
| CVU | 1137743 |
| Institución |
SIN INSTITUCIÓN
|
|---|---|
| Dependencia | NO APLICA |
| Entidad | NO APLICA |
| Nivel | C |
| Vigencia | Inicio: 01/01/2023 |
| Fin: 31/12/2026 |
* Información del primer trimestre de 2026.
Fuente: SECIHTI.
Publicaciones ORCID
- 2022
- A high number of co-occurring genomic alterations detected by NGS is associated with worse clinical outcomes in advanced EGFR-mutant lung adenocarcinoma: Data from LATAM population Lung Cancer
- Modifying factors of PD‐L1 expression on tumor cells in advanced non‐small‐cell lung cancer Thoracic Cancer
- Quality of life, anxiety, depression, and distress in patients with advanced and metastatic lung cancer Palliative and Supportive Care
- A High Number of Co-Occurring Genomic Alterations Detected by NGS is Associated with Worse Clinical Outcomes in Advanced EGFR-Mutant Lung Adenocarcinoma: Data from LATAM Population
- 2021
- Clinical Impact of the COVID-19 Pandemic in Mexican Patients with Thoracic Malignancies The Oncologist
- Impact of detecting plasma EGFR mutations with ultrasensitive liquid biopsy in outcomes of NSCLC patients treated with first- or second-generation EGFR-TKIs Cancer Biomarkers
- Brigatinib in ALK-positive non-small cell lung cancer: real-world data in the Latin American population (Bri-world extend CLICaP) Future Oncology
- 2020
- Recommendations for detection, prioritization, and treatment of thoracic oncology patients during the COVID-19 pandemic: the THOCOoP cooperative group. Critical reviews in oncology/hematology